Center-Authored Papers

Filters: Author is Unger, Joseph M  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Z
Zirpoli GR, Brennan PM, Hong C-C, McCann SE, Ciupak G, Davis W, Unger JM, Thomas Budd G, Hershman DL, Moore HCF et al..  2013.  Supplement use during an intergroup clinical trial for breast cancer (S0221).. Breast cancer research and treatment. 137(3):903-13. Abstract
V
Van Poznak CH, Darke A, Moinpour CM, Bagramian RA, Schubert MM, Gralow JR, Wade JL, Unger JM.  2016.  Dental health status and patient-reported outcomes at baseline in patients participating in the osteonecrosis of the jaw registry study, SWOG S0702.. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. Abstract
U
Unger JM, LeBlanc M, Blanke CD.  2017.  The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population.. JAMA oncology. Abstract
Unger JM, Barlow WE, Martin DP, Ramsey SD, LeBlanc M, Etzioni R, Hershman DL.  2014.  Comparison of Survival Outcomes Among Cancer Patients Treated In and Out of Clinical Trials.. Journal of the National Cancer Institute. Abstract
Unger JM, Hershman DL, Martin D, Etzioni RB, Barlow WE, LeBlanc M, Ramsey SD.  2015.  The diffusion of docetaxel in patients with metastatic prostate cancer.. Journal of the National Cancer Institute. 107(2) Abstract
Unger JM, Till C, Thompson IM, Tangen CM, Goodman PJ, Wright JD, Barlow WE, Ramsey SD, Minasian LM, Hershman DL.  2016.  Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.. Journal of the National Cancer Institute. 108(12) Abstract
Unger JM, Cook E, Tai E, Bleyer A.  2016.  The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies.. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. 35:185-98. Abstract
Unger JM, Hershman DL, Arnold KB, Loomba R, Chugh R, Hwang JP, O'Rourke MA, Bhadkamkar NA, Wang LX, Siegel AB et al..  2016.  Stepwise development of a cancer care delivery research study to evaluate the prevalence of virus infections in cancer patients.. Future oncology (London, England). Abstract
Unger JM, Hershman DL, Albain KS, Moinpour CM, Petersen JA, Burg K, Crowley JJ.  2013.  Patient income level and cancer clinical trial participation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(5):536-42. Abstract
Unger JM, Gralow JR, Albain KS, Ramsey SD, Hershman DL.  2016.  Patient Income Level and Cancer Clinical Trial Participation: A Prospective Survey Study.. JAMA oncology. 2(1):137-9.
Unger JM, Barlow WE, Hershman DL.  2016.  Measuring the Real Clinical Impact of Randomized Clinical Trials in Oncology-Reply: Beyond Citation Counts.. JAMA oncology. 2(11):1511.
Unger JM, Barlow WE, Ramsey SD, LeBlanc M, Blanke CD, Hershman DL.  2016.  The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials.. JAMA oncology. Abstract
T
Thompson JA, Fisher RI, LeBlanc M, Forman SJ, Press OW, Unger JM, Nademanee AP, Stiff PJ, Petersdorf SH, Fefer A.  2008.  Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomiz. Blood. 111(8):4048-54. Abstract
S
Stopeck AT, Unger JM, Rimsza LM, LeBlanc M, Farnsworth B, Iannone M, Glenn MJ, Fisher RI, Miller TP.  2012.  A phase II trial of standard dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.. Blood. Abstract
Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, LeBlanc M, Fisher RI, Miller TP.  2009.  A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.. Leukemia & lymphoma. 50(5):728-35. Abstract
Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS et al..  2013.  Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.. The New England journal of medicine. 369(18):1681-90. Abstract
Stasik CJ, Nitta H, Zhang W, Mosher CH, Cook JR, Tubbs RR, Unger JM, Brooks TA, Persky DO, Wilkinson ST et al..  2010.  Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma.. Haematologica. 95(4):597-603. Abstract
R
Rimsza LM, Unger JM, Tome ME, LeBlanc M.  2011.  A strategy for full interrogation of prognostic gene expression patterns: exploring the biology of diffuse large B cell lymphoma.. PloS one. 6(8):e22267. Abstract
Rimsza LM, LeBlanc M, Unger JM, Miller TP, Grogan TM, Persky DO, Martel RR, Sabalos CM, Seligmann B, Braziel RM et al..  2008.  Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.. Blood. 112(8):3425-33. Abstract
P
Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK et al..  2013.  Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(3):314-20. Abstract
Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Fisher RI.  2006.  Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(25):4143-9. Abstract
Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK et al..  2013.  A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP-Rituximab versus CHOP + 131Iodine--Tositumomab.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(23):6624-32. Abstract
Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI.  2003.  A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.. Blood. 102(5):1606-12. Abstract
Potkul RK, Unger JM, Livingston RB, Crew KD, Wilczynski SP, Salomon CG, Smith BL, Wong L, Campbell DL, Einspahr DE et al..  2016.  Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630.. NPJ breast cancer. 2:16024. Abstract
Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea DB, Press OW, Constine LS, Barton KP, Friedberg JW et al..  2015.  Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313.. Blood. 125(2):236-41. Abstract